SRPT
Sarepta Therapeutics, Inc.
Biotechnology · Healthcare · United States
19.23
close · 2026-10-29
value
83
cheaper than peers83
quality
52
stronger fundamentals52
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 0.92× | 98 |
| forward P/E | 7.85× | 93 |
| price to book | 1.33× | 81 |
| EV to EBITDA | 42.50× | 24 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 13.0% | 83 |
| return on equity | -9.5% | 78 |
| debt to equity | 69.5% | 26 |
| revenue growth | -34.3% | 24 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | $22.1M |
| employees | 835 |
| first trade | 1997-06-04 |
| next earnings | 2026-11-05 |
| fundamentals updated | 2026-08-10 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -7.13 | 2.34 | -5.80 | -8.03 |
| free cash flow | -$315.3M | -$352.7M | -$588.3M | -$357.6M |
| net income | -$713.4M | $235.2M | -$536.0M | -$703.5M |
| revenue | $2.20B | $1.90B | $1.24B | $933.0M |
| unusual items | -$41.1M | -$10.6M | -$417.3M | -$121.3M |